Sign In
Buy SNDX
$18.34
-0.0500 (-0.272%)
At Close: Jun 03, 2026
ETON Up as FDA Accepts NDA for Dehydrated Alcohol Injection
12:02pm, Thursday, 12'th Jan 2023
Eton (ETON) gains as the its new drug application (NDA) for dehydrated alcohol injection for methanol poisoning is accepted for review by the FDA.
Syndax Pharmaceuticals (SNDX) Stock Sinks As Market Gains: What You Should Know
11:15pm, Wednesday, 11'th Jan 2023 Zacks Investment Research
In the latest trading session, Syndax Pharmaceuticals (SNDX) closed at $25.62, marking a -1.16% move from the previous day.
Biogen's (BIIB) Partner Eisai Files MAA for Lecanemab in Europe
02:38pm, Wednesday, 11'th Jan 2023 Zacks Investment Research
Biogen's (BIIB) partner Eisai files a marketing authorization application to the European Medicines Agency for lecanemab for treating early Alzheimer's disease in Europe.
bluebird (BLUE) Updates on Progress With Zynteglo, 2023 Outlook
06:16pm, Tuesday, 10'th Jan 2023 Zacks Investment Research
bluebird bio, Inc. (BLUE) updates on the launch of gene therapy Zynteglo and provides cash burn guidance for 2023.
Editas (EDIT) Dips on Portfolio Reprioritization, To Cut Jobs
05:06pm, Tuesday, 10'th Jan 2023 Zacks Investment Research
Editas (EDIT) enters a restructuring and portfolio reprioritization to focus on hemoglobinopathies and in vivo gene editing. The company is to reduce its workforce by almost 20%. Shares fall.
Ultragenyx (RARE) Posts Preliminary '22 Results, Gives '23 View
06:34pm, Monday, 09'th Jan 2023 Zacks Investment Research
Ultragenyx (RARE) reports preliminary product revenues for its marketed drugs, Crysvita, Mepsevii and Dojolvi for the full year 2022. The company issues product revenue guidance for 2023.
Exelixis (EXEL) Announces Preliminary Q4 and 2022 Results
06:33pm, Monday, 09'th Jan 2023 Zacks Investment Research
Exelixis (EXEL) reports preliminary revenues for the fourth quarter and 2022. It also provides guidance for 2023 and pipeline updates.
Alnylam (ALNY) Posts Strong Preliminary Revenues for 4Q & FY22
06:22pm, Monday, 09'th Jan 2023 Zacks Investment Research
Alnylam (ALNY) reports strong preliminary product revenues for its marketed drugs, Onpattro, Amvuttra, Givlaari and Oxlumo for the fourth quarter and full year of 2022.
FATE To End Janssen Deal and Prioritize Pipeline Development
06:55pm, Friday, 06'th Jan 2023 Zacks Investment Research
FATE decides not to continue its collaboration and option agreement with Janssen. The company also conducts a strategic review.
FDA Accepts AstraZeneca (AZN), Sanofi's RSV Antibody BLA
06:50pm, Friday, 06'th Jan 2023 Zacks Investment Research
The FDA's decision on AstraZeneca (AZN)/Sanofi's (SNY) regulatory filing, seeking approval for using their RSV antibody in all infants, is expected in third-quarter 2023.
Roche's (RHHBY) Cancer Drug Glofitamab Gets FDA Priority Review
03:52pm, Friday, 06'th Jan 2023 Zacks Investment Research
The FDA accepts and grants priority review to Roche's (RHHBY) biologics license application for glofitamab to treat relapsed or refractory large B-cell lymphoma. The decision is due on Jul 1, 2023.
Geron (GERN) Up on Imetelstat Data on Myelodysplastic Syndromes
07:04pm, Thursday, 05'th Jan 2023 Zacks Investment Research
Geron (GERN) posts positive top-line data from the phase III IMerge study investigating its lead candidate, imetelstat for treating lower risk myelodysplastic syndromes. Shares up.
Phathom (PHAT) Down on Regulatory Update on Vonoprazan NDA
03:42pm, Thursday, 05'th Jan 2023 Zacks Investment Research
Phathom Pharmaceuticals, Inc. (PHAT) declines as the FDA decides to not take any action on Phathom's new drug application (NDA) for vonoprazan for treating erosive esophagitis.
VERA Dips Despite Positive Data From IgA Nephropathy Study
05:20pm, Wednesday, 04'th Jan 2023 Zacks Investment Research
VERA posts positive top-line data from the phase IIb ORIGIN study evaluating atacicept for the treatment of IgA nephropathy.
Deciphera (DCPH) Issues Strategic & Corporate Outlook for 2023
05:16pm, Wednesday, 04'th Jan 2023 Zacks Investment Research
Deciphera (DCPH) provides a strategic outlook and planned corporate milestones for 2023. The company also posts preliminary fourth-quarter and 2022 revenues.
